This week in techniques

Approach

Summary

Licensing status

Publication and contact information

Drug platforms

Modular, noncovalent conjugate vaccines to prevent bacterial infection

In vitro and mouse studies suggest modular, noncovalent conjugate vaccines could be useful for preventing bacterial infections. A pneumococcal peptide antigen fused to the biotin-binding protein rhizavidin was co-incubated with a biotinylated bacterial polysaccharide to form a tightly associated noncovalent complex. Mice vaccinated with the complex had better B and T cell responses and survival than controls inoculated with conventional pneumococcal conjugate vaccine. Next steps include developing a multivalent version of the vaccine targeting other bacterial antigens.
GlaxoSmithKline plc's Synflorix and Pfizer Inc.'s Prevnar and
Prevnar 13 pneumococcal conjugate vaccines are marketed to prevent pneumococcal disease.

SciBX 6(35); doi:10.1038/scibx.2013.979
Published online Sept. 12, 2013

Method of construction of noncovalent conjugate vaccines subject to a pending patent; available for licensing

Zhang, F. et al. Proc. Natl. Acad. Sci. USA; published online July 29, 2013;
doi:10.1073/pnas.1307228110
Contact: Richard Malley, Boston Children's Hospital, Boston, Mass.
e-mail:
richard.malley@childrens.harvard.edu